Cheryl Gault - 26 Nov 2025 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Chief Operating Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
RAPP
Transactions as of
26 Nov 2025
Transactions value $
-$141,487
Form type
4
Filing time
01 Dec 2025, 16:17:37 UTC
Previous filing
10 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gault Cheryl Chief Operating Officer RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON /s/ Troy Ignelzi, Attorney-in-Fact 01 Dec 2025 0001839046

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Options Exercise $9K +5K +2.91% $1.80 177K 26 Nov 2025 Direct F1
transaction RAPP Common Stock Sale -$150K -5K -2.83% $30.10 172K 26 Nov 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAPP Stock Option (Right to Buy) Options Exercise $0 -5K -4.53% $0.00 105K 26 Nov 2025 Common Stock 5K $1.80 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.